Skip to main
KMTS

KMTS Stock Forecast & Price Target

KMTS Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Kestra Medical Techs is a commercial-stage medical device and digital healthcare company with a promising product portfolio that targets cardiovascular disease. The company has shown strong progress through consistent improvement in conversion rate drivers, and has gained market share as well as expanded its reach to new prescribers. With a growing salesforce, ongoing product updates, and strategic collaborations, Kestra is well-positioned for potential durable revenue acceleration and gross margin expansion. While risks include commercial challenges and regulatory decisions, the company's solid financial profile and potential for further market share growth make it a favorable investment opportunity.

Bears say

Kestra Medical Techs is a commercial-stage MedTech company that has developed the ASSURE Cardiac Recovery System, including the wearable ASSURE WCD, which has received FDA PMA approval and has been commercially available since August 2022. Despite recent improvements in field team expansion and prescription trends, the company still faces challenges in driving conversion rate and reaching full productivity of new reps. Additionally, while there have been steady margin expansions, it remains unclear when the company will reach 70%+ margins or how the updates to the new algorithm will be implemented on all existing systems.

KMTS has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kestra Medical Technologies Inc (KMTS) Forecast

Analysts have given KMTS a Buy based on their latest research and market trends.

According to 4 analysts, KMTS has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kestra Medical Technologies Inc (KMTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.